Financial Performance - For the nine months ended December 31, 2020, the group's revenue was HKD 45,745,000, a decrease of 8.1% compared to HKD 49,249,000 for the same period in 2019[7]. - Gross profit for the nine months was HKD 25,169,000, representing a slight decrease of 2.1% from HKD 25,711,000 in the previous year[7]. - The net profit attributable to the owners of the company for the nine months was HKD 7,729,000, down 2.3% from HKD 7,914,000 in the same period last year[7]. - Basic earnings per share for the nine months was HKD 0.97, compared to HKD 0.99 for the same period in 2019[7]. - Total comprehensive income for the three months ended December 31, 2020, was HKD 2,035,000, down from HKD 3,331,000 in the same period of 2019, a decrease of 38.9%[7]. - The group reported a profit attributable to owners of the company of HKD 7,729,000 for the nine months ended December 31, 2020, a decrease from HKD 7,914,000 in the previous year[47]. - The company recorded a profit of approximately HKD 7,700,000 for the nine months ended December 31, 2020, down from HKD 7,900,000 in the same period of 2019[65]. Revenue and Expenses - The group incurred administrative and other operating expenses of HKD 17,038,000 for the nine months, an increase of 8.1% from HKD 15,754,000 in the previous year[7]. - Financial costs for the nine months were HKD 70,000, down from HKD 149,000 in the previous year, a decrease of 53.0%[7]. - The group incurred research and development expenses of approximately HKD 363,000 for the nine months ended December 31, 2020, compared to HKD 432,000 in the same period of 2019[36]. - Administrative and other operating expenses increased by approximately HKD 1,200,000 or 8.2% to about HKD 17,000,000 for the nine months ended December 31, 2020, primarily due to an increase in the workforce[59]. Revenue Trends - The group reported a revenue of HKD 15,100,000 for the three months ended December 31, 2020, a decrease of 12.5% compared to HKD 17,248,000 in the same period of 2019[26]. - For the nine months ended December 31, 2020, the revenue was HKD 45,745,000, down 7.6% from HKD 49,249,000 in the previous year[26]. - Revenue from a major customer amounted to HKD 5,459,000, representing over 10% of the group's total revenue for the nine months ended December 31, 2020[27]. - The company's revenue decreased by approximately 7.1% from about HKD 49,200,000 in the nine months ended December 31, 2019, to about HKD 45,700,000 in the nine months ended December 31, 2020[57]. Dividends and Shareholder Information - The group did not declare an interim dividend for the nine months ended December 31, 2020, consistent with the previous year[41]. - The company did not declare an interim dividend for the nine months ended December 31, 2020[66]. - As of December 31, 2020, B&A Success holds 557,424,000 shares, representing 69.68% of the company's total equity[77]. - The company has a stock option plan that allows for the issuance of up to 80,000,000 shares, which is 10% of the total shares issued at the time of listing[78]. - At the end of the reporting period, a total of 71,940,000 shares are available for issuance under the stock option plan, accounting for 8.99% of the company's total issued share capital[81]. - No shares were purchased, sold, or redeemed by the company or its subsidiaries during the nine months ending December 31, 2020[87]. Market and Strategic Outlook - The company has not announced any new products or technologies during this reporting period[14]. - There are no significant market expansion or acquisition strategies mentioned in the report[14]. - The company is supplying Hong Kong's first pharmacy automation system, which is expected to address healthcare labor shortages and instill confidence in potential clients[54]. - The company plans to further expand its product portfolio and enhance customer service to improve its one-stop medical equipment solution services[54]. - The economic impact of COVID-19 has significantly affected customer spending plans, leading to challenges for the company's clients[54]. - The company remains optimistic about the healthcare sector's prospects due to the growing elderly population and increasing medical awareness among Hong Kong citizens[54]. - The company continues to monitor the developments of COVID-19 and its potential impact on financial performance[51]. Compliance and Audit - The audit committee has reviewed the unaudited consolidated financial statements for the nine months ending December 31, 2020, and confirmed compliance with applicable accounting standards and GEM listing rules[96]. - The group’s total non-current assets are primarily located in Hong Kong, with all revenue generated from this region[24]. - The group has only one operating segment as per the Hong Kong Financial Reporting Standards, focusing on the supply of medical instruments and related solutions[23]. - The group’s interest expenses on lease liabilities were HKD 70,000 for the nine months ended December 31, 2020, down from HKD 149,000 in the previous year[33]. - The group’s bank interest income decreased to HKD (346,000) for the nine months ended December 31, 2020, compared to HKD (693,000) in the same period of 2019[36]. - Gross profit for the nine months ended December 31, 2020, was approximately HKD 25,200,000, compared to HKD 25,700,000 for the same period in 2019, with the gross profit margin increasing from 52.2% to 55.0%[58].

Grand Brilliance Group Holdings Limited 君百延集團控股有限公司 (於開曼群島註冊成立的有限公司) 股份代號：8372 BOODORDOOD 香港聯合交易所有限公司（「香港聯交所」）GEM的特色 GEM的定位乃為相比起其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應瞭解投資該等公司的潛在風險，並應經過 審慎周詳考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然，在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告（君百延集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」或「我 們」）各董事（「董事」）願就此共同及個別承擔全部責任）乃遵照香港聯交所GEM證券 上市規則（「GEM上市 ...

Financial Performance - For the three months ended June 30, 2020, the company reported revenue of HKD 14,010,000, a decrease of 3.2% from HKD 14,471,000 in the same period of 2019[7] - Gross profit for the same period was HKD 8,200,000, representing an increase of 6.2% compared to HKD 7,719,000 in 2019[7] - The company recorded a profit before tax of HKD 3,391,000, up 57.0% from HKD 2,160,000 in the previous year[7] - Net profit attributable to owners of the company was HKD 2,920,000, an increase of 68.8% from HKD 1,731,000 in the same quarter of 2019[7] - Basic and diluted earnings per share for the period were HKD 0.37, compared to HKD 0.22 in the previous year, reflecting a growth of 68.2%[7] - Other income increased significantly to HKD 1,035,000 from HKD 228,000, marking a growth of 353.5% year-on-year[7] - The group reported a tax expense of 471,000 HKD for the three months ended June 30, 2020, compared to 429,000 HKD for the same period in 2019, reflecting an increase of about 9.8%[77] - Profit for the period was approximately HKD 2,900,000 for the three months ended June 30, 2020, compared to HKD 1,700,000 for the same period in 2019, primarily due to increased other income and gross profit[105] Revenue Breakdown - Revenue from medical consumables was 11,748,000 HKD in Q2 2020, up from 10,530,000 HKD in Q2 2019, indicating an increase of approximately 11.5%[69] - The group recognized contract revenue of 13,951,000 HKD for the three months ended June 30, 2020, compared to 14,431,000 HKD in the same period of 2019, reflecting a decline of about 3.3%[69] - The group had a significant customer contributing approximately 2,892,000 HKD, accounting for over 10% of total revenue for the three months ended June 30, 2020, whereas no single customer contributed over 10% in the same period of 2019[66] Expenses and Costs - The company incurred finance costs of HKD 16,000, a decrease of 67.3% from HKD 49,000 in the same period last year[7] - Distribution and selling expenses were HKD 210,000, a decrease from HKD 258,000 in the previous year, indicating a reduction of 18.6%[7] - Administrative and other operating expenses increased by approximately HKD 200,000 or 3.6% to HKD 5,700,000 for the three months ended June 30, 2020, mainly due to increased employee costs[101] - Research and development expenses for the three months ended June 30, 2020, were approximately 112,000 HKD, compared to 132,000 HKD for the same period in 2019[74] Corporate Governance - The company has adhered to all provisions of the corporate governance code, with the exception of the chairman and CEO roles being held by the same individual[165] - The company confirmed that all directors complied with the trading standards and relevant codes of conduct during the reporting period[160] - The audit committee, established on March 1, 2018, reviewed the unaudited condensed consolidated financial statements for the three months ended June 30, 2020, ensuring compliance with applicable accounting standards[169] - The company has established independent checks to ensure the effectiveness and independence of the board despite the dual role of the chairman and CEO[166] Share Options and Equity - As of June 30, 2020, B&A Success holds 557,424,000 shares, representing approximately 69.68% of the company's equity[150] - The company adopted a share option scheme on March 1, 2018, allowing selected participants to be granted options as an incentive for their contributions[153] - As of June 30, 2020, a total of 22,460,000 share options were available, with 21,460,000 remaining after accounting for 1,000,000 options exercised[154] - The exercise price for the share options granted on April 18, 2019, is HKD 0.12 per share[156] - No share options were granted, exercised, forfeited, cancelled, or lapsed during the three months ended June 30, 2020[156] Market and Product Development - The company has not announced any new products or technologies during this reporting period[6] - There are no updates on market expansion or mergers and acquisitions mentioned in the report[6] - The company is the first to supply an automated system for operating rooms in Hong Kong, addressing healthcare labor shortages and enhancing confidence among potential clients[96] - The company plans to further diversify its product portfolio and enhance customer service to improve its one-stop medical equipment solution services[96] - The economic impact of COVID-19 significantly affected the number of travelers from mainland China to Hong Kong, posing challenges for client businesses[96] - The company maintains a positive outlook on the healthcare sector due to the growing elderly population and increasing medical awareness among Hong Kong citizens[96] Dividends - The group did not recommend any dividend for the three months ended June 30, 2020, consistent with the same period in 2019[78] - No dividend was declared for the three months ended June 30, 2020, consistent with the previous period[106]

Financial Performance - For the fiscal year ending March 31, 2020, the company's revenue increased by approximately 15.9% to about HKD 67.2 million from approximately HKD 58 million for the previous fiscal year[13]. - Gross profit rose by approximately HKD 5 million or 15.9% to about HKD 36.4 million, maintaining a stable gross margin of approximately 54.1% for 2020 compared to 54.2% for 2019[14]. - The group's profit increased from approximately HKD 6,600,000 for the year ended March 31, 2019, to approximately HKD 9,600,000 for the year ended March 31, 2020, representing an increase of about 45.5%[18]. - Income tax expense for the fiscal year was approximately HKD 2.3 million, up from HKD 1.6 million in the previous year[17]. - The company reported a total revenue of HKD 578,000 for the fiscal year ending March 31, 2020, for audit services provided by its auditor[111]. - Total revenue for FY2020 was approximately HKD 67.2 million, compared to HKD 58 million in FY2019[171]. Operational Strategy - The company plans to expand its product portfolio and enhance customer service to improve its one-stop medical device solution offerings[12]. - The company aims to leverage its strengths to diversify its product offerings and expand its customer base amid challenges from the US-China trade war and COVID-19[9]. - The company has strengthened its operational team resources to ensure timely delivery of products and support business growth[12]. - The company has recruited talent across various business departments to support and sustain business growth[12]. - The company has implemented new operational strategies to improve efficiency, which are expected to reduce costs by G% in the upcoming year[49]. Market Outlook - The company is optimistic about the healthcare sector's prospects, driven by an aging population and increasing medical awareness among Hong Kong citizens[9]. - The company is pioneering the first pharmacy automation system in Hong Kong, which is expected to address healthcare labor shortages[9]. - The company is expanding its market presence in the Greater Bay Area, targeting a D% increase in market share over the next two years[49]. - New product launches are anticipated to contribute an additional C million in revenue, with a focus on innovative technology in the healthcare sector[49]. Governance and Compliance - The company has adopted the corporate governance code as per GEM Listing Rules Appendix 15, ensuring compliance with all provisions except for one specific clause[61]. - The board of directors consists of six members, responsible for overall business development goals and long-term company strategy[65]. - The company emphasizes high standards of corporate governance to enhance corporate value and accountability, protecting shareholder interests[61]. - The company has implemented strict trading standards for directors, ensuring compliance with relevant codes of conduct[62]. - The audit committee held five meetings during the fiscal year ending March 31, 2020, reviewing the annual report, financial statements, and risk management procedures[85]. Risk Management - The company has established a risk management policy to identify, assess, and manage key business risks, with departments responsible for regular risk identification and assessment[113]. - The board confirmed its responsibility for the effectiveness and adequacy of the risk management and internal control systems, conducting quarterly reviews[113]. - The company is closely monitoring foreign exchange risks and may consider hedging measures to mitigate potential impacts on operational performance[32]. - The group has confirmed that its risk management and internal control systems are effective and adequate[114]. Environmental, Social, and Governance (ESG) - The group is committed to sustainable development and has integrated environmental, social, and governance principles into its business strategy[135]. - The group focuses on environmental, social, and governance (ESG) issues, identifying key topics through stakeholder engagement and assessments[154]. - The ESG report covers the fiscal year ending March 31, 2020, detailing activities, challenges, and measures taken in ESG areas[140]. - Total greenhouse gas emissions decreased by approximately 20.3% from about 69 tons of CO2 equivalent in FY2019 to about 55 tons in FY2020[164]. - The group has implemented environmental policies aimed at reducing resource usage and promoting recycling and waste management principles[161]. Employee Welfare - The company has a total of 33 full-time employees as of March 31, 2020[190]. - Employee turnover rate is 83.9% for males and 57.1% for females[193]. - The company has not recorded any work-related fatalities, indicating a work-related death rate of zero[199]. - The company has implemented air purification equipment to ensure good indoor air quality in the workplace[186]. - The company is committed to maintaining a safe and healthy work environment through regular monitoring and training[200].

Grand Brilliance Group Holdings Limited 君百延集團控股有限公司 (於開曼群島註冊成立的有限公司) 股份代號：8372 香港聯合交易所有限公司(「香港聯交所」) GEM 的特色 GEM 的定位乃為相比超其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應瞭解投資該等公司的潛在風險,並應經過 審慎周詳考慮後方作出投資決定。GEM 的較高風險及其他特色表示GEM 較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然,在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責,對其準確性或 完整性亦不發表任何聲明,並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告(君百延集團控股有限公司(「本公司」,連同其附屬公司統稱「本集團」或「我 們」} 各 董 李 (「 董 李 [ 董 李 [ 董 ] ] 」 上市規則([GEM上市規則])提供有關本集團的資料 ...

Financial Performance - The group's revenue for the six months ended September 30, 2019, was HKD 32,001,000, representing an increase of 14.3% compared to HKD 28,004,000 for the same period in 2018[9]. - Gross profit for the same period was HKD 16,886,000, with a gross margin of 52.8%, compared to HKD 16,024,000 and a gross margin of 57.2% in 2018[9]. - The net profit attributable to the owners of the company for the period was HKD 4,583,000, compared to a loss in the previous year[9]. - The basic and diluted earnings per share for the period were HKD 0.57[9]. - Revenue from medical consumables was HKD 23,191,000, up from HKD 19,331,000, representing a growth of 20.1% year-over-year[52]. - The company reported a profit attributable to owners of HKD 4,583,000 for the six months ended September 30, 2019, a decrease of 15.0% from HKD 5,393,000 in the same period of 2018[69]. - The group recorded a profit of approximately HKD 4,600,000 for the six months ended September 30, 2019, a decrease of about HKD 800,000 or 14.8% compared to HKD 5,400,000 for the same period in 2018[119]. Cash Flow and Assets - Cash and cash equivalents at the end of the period increased to HKD 62,894,000 from HKD 53,369,000 in 2018, reflecting a net increase of HKD 8,951,000[18]. - The net cash generated from operating activities was HKD 8,623,000, compared to a net cash used of HKD 3,435,000 in the previous year[18]. - Total assets as of September 30, 2019, were HKD 83,212,000, an increase from HKD 81,196,000 as of March 31, 2019[11]. - As of September 30, 2019, current assets were approximately HKD 90,500,000, an increase from HKD 85,200,000 as of March 31, 2019[121]. Liabilities and Equity - The company’s total liabilities included lease liabilities of HKD 2,342,000, with current lease liabilities at HKD 2,027,000 and non-current lease liabilities at HKD 315,000[1]. - The company confirmed a provision for impairment of trade receivables amounting to HKD 1,478,000 as of September 30, 2019[80]. - Trade payables amounted to HKD 3,630,000 as of September 30, 2019, down from HKD 7,358,000 as of March 31, 2019[86]. Dividends - The company declared a dividend of HKD 3,500,000 during the period[14]. - The board resolved not to declare an interim dividend for the six months ended September 30, 2019[120]. - The company did not declare an interim dividend for the six months ended September 30, 2019, consistent with the previous year[66]. Operational Developments - The group continues to focus on expanding its medical equipment supply and solutions business, including market trend analysis and after-sales services[19]. - The company is committed to enhancing its technological support and training services for medical equipment[19]. - The group has introduced Hong Kong's first pharmacy automation system, enhancing its service offerings and addressing healthcare labor shortages[110]. - The company plans to expand its product portfolio and enhance customer service to improve its one-stop medical device solution services[110]. - The group is actively seeking strategic acquisition opportunities and has been carefully identifying potential targets[139]. - The group has hired a software engineer to enhance product development capabilities and is researching several medical and healthcare automation solutions[139]. - The group has participated in various exhibitions, including the 2019 Hospital Authority Conference and the Hong Kong International Medical and Healthcare Fair, to further penetrate the medical device market and increase market share[139]. Employee and Workforce - As of September 30, 2019, the group had a total of 33 employees, an increase from 27 employees as of March 31, 2019, with employee costs amounting to approximately HKD 7,400,000 for the six months ended September 30, 2019, compared to HKD 5,300,000 for the same period in 2018[134]. - The group has expanded its workforce by hiring five sales supervisors, two engineers, and one warehouse staff, and is in the process of recruiting high-quality employees[139]. Compliance and Governance - The company confirmed compliance with the non-competition agreement made on March 1, 2018, by its controlling shareholders[175]. - The company has adhered to all provisions of the corporate governance code as of September 30, 2019, with some exceptions noted[176]. - The audit committee has reviewed the unaudited consolidated financial statements for the six months ended September 30, 2019, confirming compliance with applicable accounting standards and GEM listing rules[183].

Financial Performance - For the three months ended June 30, 2019, the company reported revenue of HKD 14,471,000, an increase of 5.3% compared to HKD 13,742,000 in the same period of 2018[7] - Gross profit for the same period was HKD 7,719,000, down 4.3% from HKD 8,070,000 year-over-year[7] - The company's profit before tax decreased to HKD 2,160,000, a decline of 35.3% from HKD 3,363,000 in the prior year[7] - Net profit attributable to owners of the company was HKD 1,731,000, representing a decrease of 36.8% compared to HKD 2,737,000 in the same quarter of 2018[7] - Basic and diluted earnings per share for the period were HKD 0.22, down from HKD 0.34 in the previous year[7] - The group reported revenue of HKD 14,070,000 for the three months ended June 30, 2019, compared to HKD 13,260,000 for the same period in 2018, representing an increase of approximately 6.1%[32] - Revenue from medical consumables was HKD 10,530,000, up from HKD 9,884,000 in 2018, reflecting a growth of about 6.5%[38] - The group reported a profit before tax of HKD 429,000 for the three months ended June 30, 2019, down from HKD 626,000 in 2018, indicating a decrease of approximately 31.5%[46] - The company recorded a profit of approximately HKD 1,700,000 for the three months ended June 30, 2019, a decrease of about HKD 1,000,000 or 36.8% from approximately HKD 2,700,000 for the same period in 2018[74] Expenses and Liabilities - The company incurred administrative and other operating expenses of HKD 5,499,000, an increase of 22.6% from HKD 4,483,000 in the same period last year[7] - The group incurred research and development expenses of approximately HKD 132,000 for the three months ended June 30, 2019, compared to HKD 116,000 for the same period in 2018[42] - Income tax expense for the three months ended June 30, 2019, was approximately HKD 400,000, compared to about HKD 600,000 for the same period in 2018[73] - The group has chosen to apply the modified retrospective approach for the adoption of HKFRS 16, which will not require restatement of prior periods[25] - The group’s total liabilities include lease liabilities recognized under HKFRS 16, which are measured at the present value of lease payments[25] - The group has opted not to recognize lease liabilities and right-of-use assets for short-term leases and low-value asset leases under HKFRS 16[25] Market and Business Strategy - The company is focused on expanding its market presence in the medical equipment sector, which includes supply and after-sales services[15] - Future outlook includes continued investment in technology support and training services for medical equipment, aiming to enhance service offerings[15] - The company plans to expand its market in respiratory products and hemostatic dressings, and is also working on the first automated delivery system in Hong Kong[65] - The company aims to enhance its one-stop medical device solutions, including market trend analysis and after-sales services[64] - The group’s operating segment is solely focused on supplying medical instruments and providing related solutions, with no separate geographical analysis due to all revenue being derived from Hong Kong[30] Shareholder Information - As of June 30, 2019, the total number of shares held by Ms. Huang is 557,424,000, representing 71.18% of the company's equity[77] - Dr. Miao, as Ms. Huang's spouse, is considered to have the same equity interest in the shares held by Ms. Huang, totaling 569,424,000 shares[77] - Mr. Chan holds 10,000,000 shares, which accounts for 1.25% of the company's equity[77] - Mr. Zhao has a controlled interest of 24,718,223 shares, representing 3.09% of the company's equity[77] - The company has adopted a share option scheme allowing for the issuance of up to 80,000,000 shares, equivalent to 10% of the total shares issued at the time of listing[91] - A total of 39,500,000 share options were offered to selected participants, with 39,000,000 options accepted and not yet exercised as of June 30, 2019[97] - The share option plan is valid for ten years from its adoption date, with specific conditions that may be applied at the discretion of the board[93] - The company aims to reward employees and selected participants through the share option plan, enhancing their contributions to the group[93] - The equity interests of major shareholders and directors have been disclosed, with no additional interests reported as of June 30, 2019[85] Corporate Governance - The company established an audit committee on March 1, 2018, which reviewed the unaudited consolidated financial statements for the three months ending June 30, 2019[114] - The chairman and CEO roles are held by the same individual, which is a deviation from corporate governance guidelines, but the board believes in its independence and effectiveness[110] - The company has adhered to all corporate governance code provisions, with minor deviations noted[109] - The compliance advisor confirmed no interests in the company's securities by its directors or employees as of June 30, 2019[113] - The independent non-executive directors confirmed compliance with the non-competition agreement during the reporting period[108] - The company confirmed compliance with the GEM listing rules regarding trading standards by all directors during the reporting period[103] - There were no conflicts of interest reported among directors in relation to competing businesses as of June 30, 2019[105]

Business Growth and Strategy - The company reported a stable business growth despite challenges in the labor market, focusing on employee welfare improvements to enhance competitiveness in the human resources market[8] - The company is committed to adjusting its development strategy based on industry changes to ensure continued growth and market relevance[9] - The company is enhancing its marketing efforts to penetrate the medical device market further and increase market share through participation in various industry events[79] - The company has actively sought strategic acquisition opportunities and is currently evaluating several potential targets[79] Product Development and Offerings - The company successfully promoted a range of new medical products, including airway management products and a pharmacy automation system, marking a significant expansion in its product offerings[8] - The company has established a one-stop medical device solution service, including market trend analysis, procurement, after-sales service, and training[11] - The company is recognized as a pioneer in introducing pharmacy automation systems in Hong Kong, which has instilled confidence in potential clients[8] - The company is developing hardware prototypes using existing safety system product samples to enhance research and product development efforts[79] Financial Performance - The group's revenue increased by approximately 8.1% from about HKD 53.7 million for the year ended March 31, 2018, to about HKD 58 million for the year ended March 31, 2019, primarily due to strong sales growth in electric beds and other bed accessories[13] - Gross profit rose by approximately HKD 1.5 million or 5.1% from about HKD 29.9 million to about HKD 31.4 million, while the gross profit margin slightly decreased from approximately 55.7% to about 54.2%[15] - The group recorded a profit of approximately HKD 6.6 million for the year ended March 31, 2019, compared to a loss of about HKD 3.1 million for the previous year, marking a significant turnaround[19] - The company aims to provide consistent returns to shareholders, proposing a final dividend of HKD 0.1250 per share and a special dividend of HKD 0.3125 per share for the fiscal year ending March 31, 2019[9] Employee and Workforce Management - The company has expanded its workforce by hiring seven sales supervisors, one assistant accountant, one administrative staff, and one service engineer, although four sales supervisors have left[79] - The company has made improvements in employee benefits to attract more personnel and strengthen its team[79] - The group employed 27 staff as of March 31, 2019, with total employee costs amounting to approximately HKD 12.7 million, up from about HKD 7.7 million in 2018[38] - The company has invested approximately HKD 13 million in its business plans, with a focus on improving employee welfare and working conditions to enhance competitiveness in the labor market[79] Corporate Governance - The company has adopted the corporate governance code as per GEM Listing Rules Appendix 15, ensuring compliance with all provisions except for A.2.1 as of the fiscal year ending March 31, 2019[95] - The board consists of seven members, including two executive directors, two non-executive directors, and three independent non-executive directors[98] - The company has established a remuneration committee to oversee compensation policies and practices for directors[94] - The board is dedicated to maintaining sound corporate governance practices to guide business development and internal controls[95] Environmental, Social, and Governance (ESG) Initiatives - The company has established an Environmental, Social, and Governance (ESG) working group consisting of directors and senior executives to assess and report on ESG matters[189] - The company aims to balance business development with environmental protection, ensuring no direct industrial pollutants are generated from its operations[198] - The company encourages stakeholder feedback on its ESG policies and performance to continuously improve sustainability efforts[188] - The company has complied with applicable environmental regulations during the reporting period and has implemented internal measures to promote a green office environment[199] Risk Management and Internal Controls - The board is responsible for risk management and internal control systems, which were assessed for effectiveness and adequacy as of March 31, 2019[176] - The company has engaged an independent professional internal control consultant to review its risk assessment and internal control systems[177] - The audit committee reviews the effectiveness of accounting and internal audit functions, providing recommendations[118] - The company has not established an internal audit department but reviews the need for one annually, considering the cost-effectiveness of external independent assessments[179]

Financial Performance - For the three months ended December 31, 2018, the company reported revenue of HKD 14,153,000, an increase of 15.5% compared to HKD 12,251,000 for the same period in 2017[6] - The gross profit for the nine months ended December 31, 2018, was HKD 22,930,000, representing an increase of 6.3% from HKD 21,576,000 in the previous year[6] - The net profit attributable to owners for the nine months ended December 31, 2018, was HKD 6,109,000, compared to a loss of HKD 458,000 in the same period of 2017[6] - The basic and diluted earnings per share for the nine months ended December 31, 2018, was HKD 0.76, compared to a loss of HKD 0.07 in the previous year[9] - The total comprehensive income for the nine months ended December 31, 2018, was HKD 6,109,000, compared to a total comprehensive loss of HKD 478,000 in the same period of 2017[9] - The group reported a profit attributable to owners of the company of HKD 6,109,000 for the nine months ended December 31, 2018, compared to a loss of HKD 458,000 in the same period of 2017[40] - The group’s profit before tax for the nine months ended December 31, 2018, was HKD 18,229,000, compared to HKD 17,320,000 for the same period in 2017, showing an increase of 5.3%[30] - The group recorded a profit of approximately HKD 6,100,000 for the nine months ended December 31, 2018, compared to a loss of about HKD 500,000 for the same period in 2017, with a decrease of about 40.0% in profit excluding non-recurring listing expenses[57] Revenue and Expenses - The company incurred administrative and other operating expenses of HKD 15,045,000 for the nine months ended December 31, 2018, which is an increase of 70.5% from HKD 8,794,000 in 2017[6] - Revenue from medical consumables for the nine months ended December 31, 2018, was HKD 27,881,000, a decrease of 4% from HKD 29,055,000 in the same period of 2017[27] - The group’s total revenue for the nine months ended December 31, 2018, was HKD 42,157,000, compared to HKD 40,005,000 for the same period in 2017, reflecting a growth of 5.4%[27] - Administrative and other operating expenses increased by approximately HKD 6,200,000 or 71.1%, from about HKD 8,800,000 for the nine months ended December 31, 2017, to about HKD 15,000,000 for the nine months ended December 31, 2018, mainly due to increased employee costs and legal fees[52] Market and Product Development - The company plans to continue expanding its market presence and enhancing its product offerings in the medical equipment sector[13] - The group aims to expand its product offerings in respiratory products, including active humidification for invasive and non-invasive ventilation, and to enhance its urology product line[47] - The group has successfully promoted airway management products applicable to various medical procedures, indicating ongoing efforts to diversify its product portfolio[47] - The group continues to engage potential clients to promote automated pharmacy systems and logistics systems for transporting medications and laboratory samples[47] Corporate Governance and Compliance - The company has adopted the corporate governance code and complied with all provisions, except for the separation of roles between the chairman and CEO[78] - The company has confirmed compliance with the non-competition agreement made on March 1, 2018, by its controlling shareholders[77] - No directors or employees violated the trading standards and codes of conduct as of December 31, 2018[73] - The company has established an audit committee consisting of two independent non-executive directors and one non-executive director[85] - The audit committee reviewed the unaudited consolidated financial statements for the nine months ending December 31, 2018, confirming compliance with applicable accounting standards and GEM listing rules[85] - The company has maintained a high level of governance and oversight despite the dual role of the chairman and CEO[81] Shareholder Information - As of December 31, 2018, B&A Success holds 557,424,000 shares, representing approximately 69.68% of the total equity[67] - No stock options were granted, exercised, expired, or lapsed during the nine months ending December 31, 2018[70] - The company did not purchase, sell, or redeem any of its listed securities during the nine months ending December 31, 2018[71] - No interim dividend was recommended for the nine months ended December 31, 2018, compared to a total dividend of HKD 14,040,000 for the same period in 2017[58] Assets and Investments - The company’s total assets as of December 31, 2018, were HKD 18,701,000, reflecting growth from previous periods[12] - The group’s total non-current assets are primarily located in Hong Kong, with no separate classification analysis presented[24] - Research and development expenses for the nine months ended December 31, 2018, were approximately HKD 360,000, compared to HKD 325,000 for the same period in 2017, indicating an increase in investment in R&D[30] - The group sourced over 10,000 types of medical instruments from more than 40 suppliers, primarily overseas manufacturers, to meet customer needs[46] - The group did not incur any non-recurring listing expenses for the nine months ended December 31, 2018, following approximately HKD 10,600,000 in related expenses for the same period in 2017[55]